MMN and P3a Elicited by a Novelty Oddball Paradigm Are Not Reduced in Early-Phase Psychosis

Riel H.a· Rudolph E.b· MacPhee C.a· Tibbo P.G.a· Fisher D.J.a,b,c

Author affiliations

aDepartment of Psychiatry, Dalhousie University, Halifax, NS, Canada
bDepartment of Psychology, Saint Mary’s University, Halifax, NS, Canada
cDepartment of Psychology, Mount Saint Vincent University, Halifax, NS, Canada

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: June 02, 2021
Accepted: August 14, 2022
Published online: November 15, 2022

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 3

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Abstract

Introduction: The present study compared the mismatch negativity (MMN) and P3a waveforms among early-phase psychosis (EPP; n = 13) individuals and healthy controls (n = 30) to contribute to the research on these waveforms as potential biomarkers for schizophrenia. Methods: MMN and P3a were elicited with a novelty paradigm using complex stimuli with electrophysiological technology. Results: No significant group differences of amplitude were observed with either waveform. Increased asociality and blunted affect were associated with a reduction in both MMN and P3a waveforms indicating a relationship between these negative symptoms and cognitive deficits. Good social and occupational functioning correlated with improved MMN and P3a waveforms in the EPP group. Conclusions: This study suggests that MMN and P3a may be more appropriately used as an indicator of illness progression and symptomology rather than a biomarker in the early phase of the illness.

© 2022 S. Karger AG, Basel

References Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl. 1998;172(S33):53–9. Cahn W, Rais M, Stigter FP, van Haren NEM, Caspers E, Hulshoff Pol HE, et al. Psychosis and brain volume changes during the first five years of schizophrenia. European Neuropsychopharmacol. 2009 Feb;19(2):147–51. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull. 1996;22(2):201–22. Harvey PD, Silverman JM, Mohs RC, Parrella M, White L, Powchik P, et al. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biological Psychiatry. 1999 Jan 1;45(1):32–40. Seidman LJ, Buka SL, Goldstein JM, Tsuang MT. Intellectual decline in schizophrenia: evidence from a prospective birth cohort 28 year follow-up study. J Clin Exp Neuropsychol. 2006 Feb;28(2):225–42. Zanelli J, Mollon J, Sandin S, Morgan C, Dazzan P, Pilecka I, et al. Cognitive change in schizophrenia and other psychoses in the decade following the first episode. Am J Psychiatry. 2019 Jul 1;176(10):811–9. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001 Jan;58(1):24–32. Jeppesen P, Petersen L, Thorup A, Abel MB, Øhlenschlæger J, Christensen TØ, et al. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med. 2008 Aug;38(8):1157–66. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005 Oct 1;162(10):1785–804. Kawakubo Y, Kasai K. Support for an association between mismatch negativity and social functioning in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(7):1367–8. Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005;62(2):127–36. Light GA, Braff DL. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry. 2005;162(9):1741–3. Rasser PE, Schall U, Todd J, Michie PT, Ward PB, Johnston P, et al. Gray matter deficits, mismatch negativity, and outcomes in schizophrenia. Schizophr Bull. 2011 Jan 1;37(1):131–40. Näätänen R, Paavilainen P, Rinne T, Alho K. The mismatch negativity (MMN) in basic research of central auditory processing: a review. Clin Neurophysiol. 2007 Dec 1;118(12):2544–90. Escera C, Corral MJ. Role of mismatch negativity and novelty-P3 in involuntary auditory attention. J Psychophysiology. 2007;21(3–4):251–64. Friedman D, Cycowicz YM, Gaeta H. The novelty P3: an event-related brain potential (ERP) sign of the brain’s evaluation of novelty. Neurosci Biobehav Rev. 2001 Jun 1;25(4):355–73. Fisher DJ, Smith DM, Labelle A, Knott VJ. Attenuation of mismatch negativity (MMN) and novelty P300 in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness. Biol Psychol. 2014 Jul;100:43–9. Horváth J, Winkler I, Bendixen A. Do N1/MMN, P3a, and RON form a strongly coupled chain reflecting the three stages of auditory distraction? Biol Psychol. 2008 Oct;79(2):139–47. Cycowicz YM, Friedman D. Effect of sound familiarity on the event-related potentials elicited by novel environmental sounds. Brain Cogn. 1998 Feb 1;36(1):30–51. Miltner W, Braun C, Johnson R, Simpson GV, Ruchkin DS. A test of brain electrical source analysis (BESA): a simulation study. Electroencephalogr Clin Neurophysiol. 1994 Oct;91(4):295–310. Atkinson RJ, Michie PT, Schall U. Duration mismatch negativity and p3a in first-episode psychosis and individuals at ultra-high risk of psychosis. Biol Psychiatry. 2012 Jan 15;71(2):98–104. Javitt DC, Doneshka P, Zylberman I, Ritter W, Vaughan HG. Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol Psychiatry. 1993 Apr 1;33(7):513–9. Kruiper C, Fagerlund B, Nielsen MØ, Düring S, Jensen MH, Ebdrup BH, et al. Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients. Psychol Med. 2019 Apr;49(5):868–75. Takahashi H, Rissling AJ, Pascual-Marqui R, Kirihara K, Pela M, Sprock J, et al. Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses. Neuroimage. 2013 Feb 1;66:594–603. Umbricht D, Koller R, Schmid L, Skrabo A, Grübel C, Huber T, et al. How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry. 2003 Jun;53(12):1120–31. Youn T, Park HJ, Kim JJ, Kim MS, Kwon JS. Altered hemispheric asymmetry and positive symptoms in schizophrenia: equivalent current dipole of auditory mismatch negativity. Schizophr Res. 2003 Feb 1;59(2–3):253–60. Hay RA, Roach BJ, Srihari VH, Woods SW, Ford JM, Mathalon DH. Equivalent mismatch negativity deficits across deviant types in early illness schizophrenia-spectrum patients. Biol Psychol. 2015 Feb;105:130–7. Mondragón-Maya A, Solís-Vivanco R, León-Ortiz P, Rodríguez-Agudelo Y, Yáñez-Téllez G, Bernal-Hernández J, et al. Reduced P3a amplitudes in antipsychotic naïve first-episode psychosis patients and individuals at clinical high-risk for psychosis. J Psychiatr Res. 2013 Jun;47(6):755–61. Nagai T, Tada M, Kirihara K, Yahata N, Hashimoto R, Araki T, et al. Auditory mismatch negativity and P3a in response to duration and frequency changes in the early stages of psychosis. Schizophr Res. 2013 Nov;150(2–3):547–54. Rudolph ED, Ells EML, Campbell DJ, Abriel SC, Tibbo PG, Salisbury DF, et al. Finding the missing-stimulus mismatch negativity (MMN) in early psychosis: altered MMN to violations of an auditory gestalt. Schizophr Res. 2015 Aug;166(1–3):158–63. Salisbury DF. Finding the missing stimulus mismatch negativity (MMN): emitted MMN to violations of an auditory gestalt. Psychophysiol. 2012 Apr 1;49(4):544–8. Fisher DJ, Rudolph ED, Ells EML, Knott VJ, Labelle A, Tibbo PG. Mismatch negativity-indexed auditory change detection of speech sounds in early and chronic schizophrenia. Psychiatry Res Neuroimaging. 2019 May;287:1–9. Ells EML, Rudolph ED, Sculthorpe-Petley L, Abriel SC, Campbell DJ, Tibbo PG, et al. Alterations of complex mismatch negativity (cMMN) elicited by a two-tone pattern paradigm in early-phase psychosis. Biol Psychol. 2018 May;135:128–35. Näätänen R, Todd J, Schall U. Mismatch negativity (MMN) as biomarker predicting psychosis in clinically at-risk individuals. Biol Psychol. 2016 Apr;116:36–40. Näätänen R, Shiga T, Asano S, Yabe H. Mismatch negativity (MMN) deficiency: a break-through biomarker in predicting psychosis onset. Int J Psychophysiol. 2015 Mar;95(3):338–44. Turetsky BI, Dress EM, Braff DL, Calkins ME, Green MF, Greenwood TA, et al. The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographic modulators in COGS-2. Schizophr Res. 2015 Apr;163(1–3):53–62. Kuehn BM. Early interventions for schizophrenia: aim to improve treatment outcomes. JAMA. 2010;304(2):139–40, 145. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci. 2010;12(3):393–407. Larson MK, Walker EF, Compton MT. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother. 2010 Aug;10(8):1347–59. Lieberman JA, Dixon LB, Goldman HH. Early detection and intervention in schizophrenia: a new therapeutic model. JAMA. 2013 Aug 21;310(7):689–90. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med. 1999 Jul;29(4):879–89. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011 Mar 1;37(2):300–5. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry. 1992 Sep;149(9):1148–56. Bright P, Jaldow E, Kopelman MD. The national adult reading test as a measure of premorbid intelligence: a comparison with estimates derived from demographic variables. J Int Neuropsychol Soc. 2002 Sep;8(6):847–54. McGrory S, Austin EJ, Shenkin SD, Starr JM, Deary IJ. From “aisle” to “labile”: a hierarchical national adult reading test scale revealed by Mokken scaling. Psychol Assess. 2015 Sep;27(3):932–43. Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry. 1987;9(1):12–35. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010 Dec 1;128(3):419–32. Thiebes S, Leicht G, Curic S, Steinmann S, Polomac N, Andreou C, et al. Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans. J Psychiatry Neurosci. 2017 Jul 1;42(4):273–83. Chong CS-Y, Siu M-W, Kwan CH-S, Chang W-C, Lee EH-M, Chan SK-W, et al. Predictors of functioning in people suffering from first-episode psychosis 1 year into entering early intervention service in Hong Kong. Early Interv Psychiatry. 2018;12(5):828–38. Higuchi Y, Sumiyoshi T, Seo T, Suga M, Takahashi T, Nishiyama S, et al. Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the Schizophrenia Cognition Rating Scale Japanese version. Schizophr Res Cogn. 2017 Mar 1;7:13–8. Haigh SM, Coffman BA, Salisbury DF. Mismatch negativity in first-episode schizophrenia: a meta-analysis. Clin EEG Neurosci. 2017;48(1):3–10. Todd J, Michie PT, Schall U, Karayanidis F, Yabe H, Näätänen R. Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biol Psychiatry. 2008;63(1):58–64. Magno E, Yeap S, Thakore JH, Garavan H, De Sanctis P, Foxe JJ. Are auditory-evoked frequency and duration mismatch negativity (mmn) deficits endophenotypic for schizophrenia? High-density electrical mapping in clinically unaffected first-degree relatives, first-episode and chronic schizophrenia. Biol Psychiatry. 2008;64(5):385–91. Curtis MT, Coffman BA, Salisbury DF. Pitch and duration mismatch negativity are associated with distinct auditory cortex and inferior frontal cortex volumes in the first-episode schizophrenia spectrum. Schizophr Bull Open. 2021;2(1):sgab005. Salisbury DF, Polizzotto NR, Nestor PG, Haigh SM, Koehler J, McCarley RW. Pitch and duration mismatch negativity and premorbid intellect in the first hospitalized schizophrenia spectrum. Schizophr Bull. 2017;43(2):407–416. Hermens DF, Ward PB, Hodge MAR, Kaur M, Naismith SL, Hickie IB. Impaired MMN/P3a complex in first-episode psychosis: cognitive and psychosocial associations. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):822–9. Kaur M, Battisti RA, Ward PB, Ahmed A, Hickie IB, Hermens DF. MMN/P3a deficits in first episode psychosis: comparing schizophrenia-spectrum and affective-spectrum subgroups. Schizophr Res. 2011 Mar 27;130(1–3):203–9. Fisher DJ, Campbell DJ, Abriel SC, Ells EML, Rudolph ED, Tibbo PG. Auditory mismatch negativity and P300a elicited by the “optimal” multi-feature paradigm in early schizophrenia. Clin EEG Neurosci. 2018 Feb 1;49(4):238–47. Molina V, Bachiller A, de Luis R, Lubeiro A, Poza J, Hornero R, et al. Topography of activation deficits in schizophrenia during P300 task related to cognition and structural connectivity. Eur Arch Psychiatry Clin Neurosci. 2019;269(4):419–28. Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: June 02, 2021
Accepted: August 14, 2022
Published online: November 15, 2022

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 3

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif